WIPOSchützen Sie diese Marke vor Nachahmern!
Mit unserer Markenüberwachung werden Sie automatisch per E-Mail über Nachahmer und Trittbrettfahrer benachrichtigt.
Die Internationale Marke LIMINAL BIOSCIENCES wurde als Wortmarke am 16.04.2020 bei der Weltorganisation für geistiges Eigentum angemeldet.
| Markenform | Wortmarke |
| Aktenzeichen | 1550716 |
| Länder | 
|
| Basismarke |
Nr. 1990944,
17. Oktober 2019
|
| Anmeldedatum | 16. April 2020 |
| Ablaufdatum | 16. April 2030 |
Markeninhaber
440 Armand-Frappier blvd,
suite 300
CA
suite 300
CA
Markenvertreter
1400 - 340 ALBERT STREET
OTTAWA ON K1R 0A5
CA
Waren und Dienstleistungen
05
Inhaled pharmaceutical preparations for the treatment of
respiratory diseases and disorders; pharmaceutical for the
treatment of erectile dysfunction; pharmaceutical
preparations and compositions for the treatment and
prevention of cancer; pharmaceutical preparations and
substances for the treatment of cancer; pharmaceutical
preparations and substances for the treatment of
gastro-intestinal diseases; pharmaceutical preparations and
substances for the treatment of gastrointestinal diseases;
pharmaceutical preparations for inhalation for the treatment
of pulmonary hypertension; pharmaceutical preparations for
the prevention and treatment of cancer; pharmaceutical
preparations for the treatment of acne; pharmaceutical
preparations for the treatment of allergies; pharmaceutical
preparations for the treatment of asthma; pharmaceutical
preparations for the treatment of autoimmune diseases;
pharmaceutical preparations for the treatment of bacterial
skin infections, fungal skin infections, viral skin
infections and parasitic skin infections; pharmaceutical
preparations for the treatment of blood disorders;
pharmaceutical preparations for the treatment of bone
diseases; pharmaceutical preparations for the treatment of
bone fractures; pharmaceutical preparations for the
treatment of brain diseases and disorders, namely, epilepsy,
alzheimer's, cerebral palsy, parkinson's disease, multiple
sclerosis; pharmaceutical preparations for the treatment of
cancer; pharmaceutical preparations for the treatment of
cardiovascular disease; pharmaceutical preparations for the
treatment of cardiovascular diseases; pharmaceutical
preparations for the treatment of carpal tunnel syndrome;
pharmaceutical preparations for the treatment of chronic
pain; pharmaceutical preparations for the treatment of
cranial or facial nerve disorders; pharmaceutical
preparations for the treatment of dandruff; pharmaceutical
preparations for the treatment of degenerative nerve
diseases and disorders, namely, alzheimer's disease,
parkinson's disease, huntington's disease and multiple
sclerosis; anti-viral agents; antibiotics; antivirals;
pharmaceutical preparations for the treatment of dental and
oral diseases; pharmaceutical preparations for the treatment
of diabetes; pharmaceutical preparations for the treatment
of diseases, disorders and infections of the endocrine
system, namely growth and thyroid disorders; pharmaceutical
preparations for the treatment of diseases, disorders and
infections of the spinal cord systems and related cartilage
and tissue; pharmaceutical preparations for the treatment of
drug and alcohol abuse; pharmaceutical preparations for the
treatment of epilepsy; pharmaceutical preparations for the
treatment of erectile dysfunction; pharmaceutical
preparations for the treatment of gastro-intestinal
diseases; pharmaceutical preparations for the treatment of
gastrointestinal disorders; pharmaceutical preparations for
the treatment of genito-urinary and pelvic diseases,
disorders and infections, namely infertility, sexually
transmitted diseases, incontinence and sexual dysfunction;
pharmaceutical preparations for the treatment of
genitourinary diseases, namely, urological diseases,
infertility, sexually transmitted diseases, inflammatory
pelvic diseases; pharmaceutical preparations for the
treatment of glaucoma; pharmaceutical preparations for the
treatment of gout; pharmaceutical preparations for the
treatment of headaches; pharmaceutical preparations for the
treatment of heart rhythm disorders; pharmaceutical
preparations for the treatment of hypercholesteremia;
pharmaceutical preparations for the treatment of
hypercholesterolemia; pharmaceutical preparations for the
treatment of hyperlipidemia; pharmaceutical preparations for
the treatment of immunologic diseases, namely, autoimmune
diseases, immunologic deficiency syndromes; pharmaceutical
preparations for the treatment of infectious diseases,
namely respiratory infections, eye infections;
pharmaceutical preparations for the treatment of
inflammatory connective tissue diseases and injuries;
pharmaceutical preparations for the treatment of
inflammatory diseases, namely, inflammatory bowel diseases,
inflammatory connective tissue diseases; pharmaceutical
preparations for the treatment of inflammatory muscle
diseases and disorders; pharmaceutical preparations for the
treatment of metabolic diseases and disorders, namely
diabetes, hypoglycaemia, gout, osteoarthritis, muscular
dystrophy, anemia; pharmaceutical preparations for the
treatment of metabolic disorders, namely diabetes, bulimia
nervosa, anorexia, obesity and hypothyroidism;
pharmaceutical preparations for the treatment of migraine;
pharmaceutical preparations for the treatment of motion
sickness; pharmaceutical preparations for the treatment of
multiple sclerosis; pharmaceutical preparations for the
treatment of myalgia and neuralgia; pharmaceutical
preparations for the treatment of neurological diseases,
namely, alzheimer's, huntington's disease, cerebral palsy;
pharmaceutical preparations for the treatment of
neurological disorders, namely, brain injury, spinal cord
injury, seizure disorders; pharmaceutical preparations for
the treatment of neuromuscular diseases and disorders,
namely, cerebrovascular accident (stroke), parkinson's
disease, multiple sclerosis, myasthenia gravis
40
Manufacture of pharmaceuticals to the order and
specification of others
42
Development of pharmaceutical preparations and medicines;
pharmaceutical product evaluation; pharmaceutical research
and development; pharmaceutical research services; research
on the subject of pharmaceuticals
44
Pharmaceutical advice; pharmaceutical consultancy services;
provision of pharmaceutical information; providing
information to patients in the field of administering
medications; medical care and analysis services relating to
patient treatment
45
Providing personal support services for families of patients
with life threatening disorders; providing companionship
services for families of patients with life threatening
disorders
Die Bezeichnungen wurden automatisch übersetzt. Übersetzung anzeigen
Markenhistorie
| Datum | Belegnummer | Bereich | Eintrag |
|---|---|---|---|
| 07. März 2022 | 2022/10 Gaz | MX | Ablehnung |
| 24. Februar 2022 | 2022/8 Gaz | JP | RAW: Rule 18ter(2)(i) GP following a provisional refusal |
| 16. November 2021 | 2021/48 Gaz | RAW: Limitation | |
| 12. November 2021 | 2021/46 Gaz | US | RAW: Rule 18ter(2)(ii) GP following a provisional refusal |
| 02. September 2021 | 2021/38 Gaz | IL | RAW: Rule 18ter(2)(i) GP following a provisional refusal |
| 26. August 2021 | 2021/35 Gaz | JP | Ablehnung |
| 19. August 2021 | 2021/33 Gaz | NO | Ablehnung |
| 15. Juli 2021 | 2021/28 Gaz | CH | Ablehnung |
| 18. Mai 2021 | 2021/20 Gaz | BR | Ablehnung |
| 30. April 2021 | 2021/17 Gaz | NZ | Ablehnung |
| 31. März 2021 | 2021/13 Gaz | TR | Ablehnung |
| 03. Februar 2021 | 2021/7 Gaz | EM | Ablehnung |
| 18. Januar 2021 | 2021/4 Gaz | CN | Ablehnung |
| 12. Januar 2021 | 2021/7 Gaz | RAW: Limitation | |
| 12. Januar 2021 | 2021/2 Gaz | AU | Ablehnung |
| 21. Dezember 2020 | 2021/1 Gaz | IL | Ablehnung |
| 10. Oktober 2020 | 2020/42 Gaz | US | Ablehnung |
| 16. April 2020 | 2020/36 Gaz | CA | Eintragung |
ID: 141550716